Stromedix raises $25 million in a Series B financing round
MORE (PDF) >
Stromedix profiled in BioCentury in October, 2007
MORE (PDF) >


Corporate Factsheet
Download our Corporate Factsheet for information on who we are and what we do.
DOWNLOAD (PDF) >
 		 
Michael Gilman, Ph.D.
Founder and Chief Executive Officer
Mike most recently served as Executive Vice President, Research at Biogen Idec and previously as Chief Scientific Officer of ARIAD Pharmaceuticals. He spent eight years on the scientific staff of Cold Spring Harbor Laboratory.

Neil Kirby, Ph.D.
Chief Development Officer
Neil was Senior Vice President, Strategic Product Development at Transkaryotic Therapies (TKT) and, prior to that, held a variety of program management and regulatory positions at Vertex, Genetics Institute and Biogen.

Brad Maroni, M.D.
Chief Medical Officer
Brad was most recently Chief Medical Officer at RenaMed Biologics. Prior to that, he was Vice President, Clinical Development at Amgen, where he was responsible for clinical development within the Anemia/Nephrology therapeutic area. He had previously spent ten years at Emory University conducting basic and clinical research.

Dan Lynch
Executive Chairman
Dan served as CFO and then CEO and a Director of ImClone Systems Inc. Prior to ImClone, he held the position of Chief Financial Officer of Derby Cycle Corporation. He also served for 15 years in various financial capacities at Bristol-Myers Squibb Company, including Vice President positions for the U.S. Pharmaceuticals business, Worldwide Manufacturing operations, International Pharmaceuticals business, and the Worldwide Consumer Medicines business.


board
Dan Lynch
Executive Chairman

Michael Gilman, Ph.D.
Founder and Chief Executive Officer

Peter Barrett, Ph.D.
Atlas Venture

Chris Gabrieli
Bessemer Venture Partners

Ron Hunt
New Leaf Venture Partners

  
STX-100 is Stromedix’ first clinical candidate and is being developed for the treatment of chronic allograft dysfunction in kidney transplant recipients.

Humanized monoclonal antibody to integrin αvβ6
Set to enter phase 1 clinical testing in early 2008
In-licensed from Biogen Idec in 2007
Provides localized, injury-specific inhibition of TGF-β activation
Significant anti-fibrotic activity in preclinical models of lung, kidney and liver disease
Broad therapeutic utility in chronic organ failure, acute organ failure and cancer